In the shadows of the brain, a protein called tau quietly tangles—and now, scientists at the University of Pittsburgh can see it coming earlier than ever before. A new brain imaging tracer called MK6240 detects the hallmark tau pathology of Alzheimer's disease before symptoms appear and with greater sensitivity than the current clinical standard, offering a window into who might benefit from emerging treatments and who won't.
For decades, researchers have chased two key villains in Alzheimer's: amyloid plaques and tau tangles. While amyloid buildup alone doesn't always lead to cognitive decline, tau seems to be the tipping point. "Tau is the biology most closely tied to symptoms and future decline," explains Tharick Pascoal, M.D., Ph.D., the corresponding author and an associate professor of psychiatry and neurology at Pitt. The protein coils up in the brain and triggers a cascade of damage, making early detection crucial for identifying who truly needs treatment versus who might face unnecessary medical procedures.
The University of Pittsburgh team, publishing their findings in The Lancet, conducted a landmark head-to-head comparison involving 682 participants who received both types of tau scans within a 45-day window. This careful design meant they were capturing the same moment in each person's disease course, allowing the researchers to see what truly mattered: which tracer was more sensitive at spotting the tau tangles hidden in the brain. The answer was clear. MK6240, which has been used primarily in research settings until now, consistently outperformed Flortaucipir, the standard tau imaging tracer used in American and European clinics.
The differences were striking. Among cognitively normal people who had amyloid buildup, MK6240 identified more than twice as many tau-positive cases as Flortaucipir—15 percent compared to just 6 percent. That translates to 23 additional cases of tau pathology per 100 people scanned. For those showing cognitive symptoms, the advantage widened further. MK6240 found tau involvement in 28 percent of participants versus 16 percent with the older tracer, representing 15 additional cases of mild cognitive impairment and 21 additional dementia cases per 100 people.
What makes this discovery practical is its timing. As anti-amyloid therapies emerge from clinical trials, neurologists need to answer a precise question: Who will actually benefit? Someone with amyloid alone might never develop symptoms. But someone with both amyloid and tau is on a collision course. "If we can detect tau earlier and stage it more precisely, we can make better decisions about who is truly on an Alzheimer's trajectory," Pascoal says. This matters enormously for clinical trials recruiting patients most likely to show improvement, and potentially for future treatment decisions as new drugs become available.
The research builds on work launched in 2021, when Pitt scientists began systematically comparing how different tracers perform. Tau PET imaging, paired with cognitive assessments and amyloid scans, is becoming a more refined diagnostic tool. For patients—many of whom seek evaluation already worried about their memory—this improved clarity could mean the difference between earlier intervention and unnecessary anxiety. As Alzheimer's treatments advance from experimental to standard care, seeing tau earlier could transform how medicine approaches one of aging's most feared diseases.